-
1
Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
Published 2012-06-01Subjects: Get full text
Article -
2
New prospects in the treatment of diabetes mellitus
Published 2012-12-01Subjects: Get full text
Article -
3
Diosmin Potentiates the Antidiabetic Effects of Linagliptin in Nicotinamide/Streptozotocin-Induced Diabetic Wistar Rats
Published 2025-04-01Subjects: Get full text
Article -
4
Linagliptin synergizes with cPLA2 inhibition to enhance temozolomide efficacy by interrupting DPP4-mediated EGFR stabilization in glioma
Published 2025-07-01Subjects: Get full text
Article -
5
-
6
Russian Association of Endocrinologists reports commencement of Trajenta clinical use
Published 2012-12-01Subjects: Get full text
Article -
7
Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
Published 2020-12-01Subjects: Get full text
Article -
8
Integrative genomic analysis identifies DPP4 inhibition as a modulator of FGF17 and PDGFRA downregulation and PI3K/Akt pathway suppression leading to apoptosis
Published 2025-07-01Subjects: “…Linagliptin…”
Get full text
Article -
9
A nanolevel sustainable fluorometric approach employing Eosin Y, a biological dye, as an innovative quenching-based biochemical sensor for linagliptin determination
Published 2025-08-01Subjects: “…Quantitative analysis of Linagliptin…”
Get full text
Article -
10
Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
Published 2013-12-01Subjects: Get full text
Article -
11